| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 7840 | 2010 |
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin, JS Kim, R Luo, J Feng, S Ye, ... The lancet oncology 10 (1), 25-34, 2009 | 6506 | 2009 |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3942 | 2017 |
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12 … YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, ... The Lancet 390 (10111), 2461-2471, 2017 | 2060 | 2017 |
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 | 1482 | 2019 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1480 | 2013 |
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study A Ohtsu, MA Shah, E Van Cutsem, SY Rha, A Sawaki, SR Park, HY Lim, ... J Clin Oncol 29 (30), 3968-3976, 2011 | 1357 | 2011 |
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial YK Kang, WK Kang, DB Shin, J Chen, J Xiong, J Wang, M Lichinitser, ... Annals of oncology 20 (4), 666-673, 2009 | 1000 | 2009 |
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ... The lancet oncology 14 (6), 490-499, 2013 | 951 | 2013 |
| Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization P Giannakakou, DL Sackett, YK Kang, Z Zhan, JTM Buters, T Fojo, ... Journal of Biological Chemistry 272 (27), 17118-17125, 1997 | 917 | 1997 |
| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 909 | 2020 |
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial AL Cheng, YK Kang, DY Lin, JW Park, M Kudo, S Qin, HC Chung, X Song, ... Journal of clinical oncology 31 (32), 4067-4075, 2013 | 827 | 2013 |
| Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors MS Beg, AJ Brenner, J Sachdev, M Borad, YK Kang, J Stoudemire, ... Investigational new drugs 35, 180-188, 2017 | 795 | 2017 |
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study JM Llovet, T Decaens, JL Raoul, E Boucher, M Kudo, C Chang, YK Kang, ... Journal of Clinical Oncology 31 (28), 3509-3516, 2013 | 651 | 2013 |
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial AX Zhu, M Kudo, E Assenat, S Cattan, YK Kang, HY Lim, RTP Poon, ... Jama 312 (1), 57-67, 2014 | 647 | 2014 |
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial C Cainap, S Qin, WT Huang, IJ Chung, H Pan, Y Cheng, M Kudo, ... Journal of Clinical Oncology 33 (2), 172, 2015 | 645 | 2015 |
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma AX Zhu, O Rosmorduc, TRJ Evans, PJ Ross, A Santoro, FJ Carrilho, ... Journal of Clinical Oncology 33 (6), 559-566, 2015 | 593 | 2015 |
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial E Van Cutsem, S de Haas, YK Kang, A Ohtsu, NC Tebbutt, J Ming Xu, ... Journal of clinical oncology 30 (17), 2119-2127, 2012 | 586 | 2012 |
| Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours DS Hong, YK Kang, M Borad, J Sachdev, S Ejadi, HY Lim, AJ Brenner, ... British journal of cancer 122 (11), 1630-1637, 2020 | 558 | 2020 |
| Management of gastric cancer in Asia: resource-stratified guidelines L Shen, YS Shan, HM Hu, TJ Price, B Sirohi, KH Yeh, YH Yang, T Sano, ... The Lancet Oncology 14 (12), e535-e547, 2013 | 519 | 2013 |
